| [1] |
ANTONIA S J, BORGHAEI H, RAMALINGAM S S, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis[J]. Lancet Oncol, 2019, 20(10): 1395-1408.
|
| [2] |
HAMID O, ROBERT C, DAUD A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J]. Ann Oncol, 2019, 30(4): 582-588.
|
| [3] |
ROBERT C, SCHACHTER J, LONG G V, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26): 2521-2532.
|
| [4] |
SEIWERT T Y, BURTNESS B, MEHRA R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965.
|
| [5] |
BRAHMER J, RECKAMP K L, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
|
| [6] |
BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
|
| [7] |
SUN J M, SHEN L, SHAH M A, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771.
|
| [8] |
KOJIMA T, SHAH M A, MURO K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148.
|
| [9] |
CHUNG H C, ROS W, DELORD J P, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478.
|
| [10] |
RECK M, RODRÍGUEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
|
| [11] |
RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128.
|
| [12] |
CHAROENTONG P, FINOTELLO F, ANGELOVA M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade[J]. Cell Rep, 2017, 18(1): 248-262.
|
| [13] |
SALEM M E, PUCCINI A, XIU J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma[J]. Oncologist, 2018, 23(11): 1319-1327.
|
| [14] |
RONAGHY A, HU S M, TANG Z Y, et al. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities[J]. Mod Pathol, 2021, 34(2): 300-313.
|
| [15] |
YI M, NIU M K, XU L P, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14(1): 10.
|
| [16] |
JIANG X J, WANG J, DENG X Y, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J]. Mol Cancer, 2019, 18(1): 10.
|
| [17] |
BRUNO F, ABONDIO P, MONTESANTO A, et al. The nerve growth factor receptor (NGFR/p75NTR): a major player in Alzheimer’s disease[J]. Int J Mol Sci, 2023, 24(4): 3200.
|
| [18] |
BOTHWELL M. Recent advances in understanding context-dependent mechanisms controlling neurotrophin signaling and function[J]. F1000Res, 2019, 8: F1000FacultyRev-F1000Facult1658.
|
| [19] |
GARCÍA-SILVA S, BENITO-MARTÍN A, NOGUÉS L, et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism[J]. Nat Cancer, 2021, 2(12): 1387-1405.
|
| [20] |
DUDÁS J, DIETL W, ROMANI A, et al. Nerve growth factor (NGF): receptor survival axis in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2018, 19(6): 1771.
|
| [21] |
WANG X, YANG T W, SHI S H, et al. Heterogeneity-induced NGF-NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti-tumor immunotherapy with PD-1 MAb in hepatocellular carcinoma[J]. Cancer Med, 2024, 13(3): e6736.
|
| [22] |
BARUCH E N, GLEBER-NETTO F O, NAGARAJAN P, et al. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy[J]. Nature, 2025, 646(8084): 462-473.
|
| [23] |
BAUST J M, BUEHRING G C, CAMPBELL L, et al. Best practices in cell culture: an overview[J]. Vitro Cell Dev Biol Anim, 2017, 53(8): 669-672.
|
| [24] |
BUSTIN S A, RUIJTER J M, VAN DEN HOFF M J B, et al. MIQE 2.0: revision of the minimum information for publication of quantitative real-time PCR experiments guidelines[J]. Clin Chem, 2025, 71(6): 634-651.
|
| [25] |
SULE R, RIVERA G, GOMES A V. Western blotting (immunoblotting): history, theory, uses, protocol and problems[J]. BioTechniques, 2023, 75(3): 99-114.
|
| [26] |
XIA Y, LIU A Q, LI W T, et al. Reference range of naïve T and T memory lymphocyte subsets in peripheral blood of healthy adult[J]. Clin Exp Immunol, 2022, 207(2): 208-217.
|
| [27] |
COSSARIZZA A, CHANG H D, RADBRUCH A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)[J]. Eur J Immunol, 2021, 51(12): 2708-3145.
|
| [28] |
BABA Y, NOMOTO D, OKADOME K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma[J]. Cancer Sci, 2020, 111(9): 3132-3141.
|
| [29] |
YU L, WEI J, LIU P D. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer[J]. Semin Cancer Biol, 2022, 85: 69-94.
|
| [30] |
ZHANG C N, GU L Q, XIAO J, et al. Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer[J]. BMC Cancer, 2023, 23(1): 684.
|